Deparment of Immunology
Moffitt Cancer Center
United States of America
Dr. Frederick Locke is affiliated to Deparment of Immunology, Moffitt Cancer Center. Dr. Frederick Locke is currently providing services as Researcher. Dr. Frederick Locke has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Frederick Locke contributions have acclaimed recognition from honourable subject experts around the world. Dr. Frederick Locke is actively associated with different societies and academies. Dr. Frederick Locke academic career is decorated with several reputed awards and funding. Dr. Frederick Locke research interests include developing strategies to promote T cell responses against tumor associated antigens for patients with cancer.
Developing strategies to promote T cell responses against tumor associated antigens for patients with cancer
Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opin Biol Ther. 2017 Jun;17(6):659-661.
Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2017 Mar;23(3):405-411.
Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May;102(5):948-957.